Leap therapeutics reports positive updated data from sirexatamab colorectal cancer study

Updated data confirms statistically significant 32% higher orr and 3.5 month longer pfs  in second-line crc patients with high dkk1 levels treated with sirexatamab plus bevacizumab and chemotherapy statistically significant 22% higher orr and 2.6 month longer pfs in patients who had not had prior anti-vegf therapy leap to host a conference call to present clinical data today, march 26, 2025, at 8:00 a.m. et cambridge, mass.
LPTX Ratings Summary
LPTX Quant Ranking